Physicians' Academy for Cardiovascular Education

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

10' education - Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt

Video navigation menu

  • Undertreatment of CV risk factors is seen globally 0:09
  • Ongoing CV outcomes trials of PCSK9 inhibitors as secondary prevention 1:21
  • CV risk reduction in diabetes 3:07
  • Long-term double antiplatelet therapy as secondary CV prevention 3:59
  • Integrating PCSK9 inhibiting therapy into primary and secondary prevention 7:57
  • How to combine anti-PCSK9 treatment with other preventive strategies? 8:53

Share this page with your colleagues and friends: